Yves Allory

14.8k total citations
227 papers, 7.0k citations indexed

About

Yves Allory is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Yves Allory has authored 227 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Pulmonary and Respiratory Medicine, 96 papers in Surgery and 58 papers in Molecular Biology. Recurrent topics in Yves Allory's work include Bladder and Urothelial Cancer Treatments (89 papers), Prostate Cancer Treatment and Research (70 papers) and Prostate Cancer Diagnosis and Treatment (62 papers). Yves Allory is often cited by papers focused on Bladder and Urothelial Cancer Treatments (89 papers), Prostate Cancer Treatment and Research (70 papers) and Prostate Cancer Diagnosis and Treatment (62 papers). Yves Allory collaborates with scholars based in France, United States and Germany. Yves Allory's co-authors include Alexandre de la Taille, Laurent Salomon, Dimitri Vordos, Francis Vacherot, François Radvanyi, András Hoznek, Stéphane Terry, Guillaume Ploussard, Nathalie Nicolaı̈ew and Jean‐Claude Courvalin and has published in prestigious journals such as Nature, New England Journal of Medicine and Nature Genetics.

In The Last Decade

Yves Allory

212 papers receiving 6.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yves Allory France	48	3.1k	3.0k	1.6k	1.3k	1.2k	227	7.0k
Chin‐Lee Wu United States	52	2.8k 0.9×	4.2k 1.4×	1.5k 0.9×	2.0k 1.5×	2.0k 1.6×	247	8.5k
Hikmat Al‐Ahmadie United States	47	3.4k 1.1×	3.3k 1.1×	3.2k 2.0×	1.8k 1.4×	2.3k 1.8×	261	8.6k
Hirotsugu Uemura Japan	39	3.9k 1.2×	2.4k 0.8×	1.1k 0.6×	1.3k 1.0×	2.1k 1.7×	367	7.1k
Brett S. Carver United States	38	3.8k 1.2×	4.6k 1.6×	1.7k 1.0×	2.9k 2.2×	1.1k 0.9×	141	8.6k
Gaëlle Fromont France	35	2.0k 0.6×	1.7k 0.6×	1.1k 0.7×	622 0.5×	825 0.7×	163	4.8k
Christopher S. Foster United Kingdom	46	2.8k 0.9×	3.9k 1.3×	777 0.5×	1.9k 1.5×	1.7k 1.3×	150	7.4k
Maria Tretiakova United States	54	3.4k 1.1×	4.5k 1.5×	1.5k 0.9×	2.1k 1.6×	3.0k 2.4×	177	10.4k
Nicolas Wernert Germany	42	1.3k 0.4×	2.5k 0.8×	840 0.5×	1.1k 0.9×	1.0k 0.8×	154	5.2k
Masatoshi Eto Japan	39	2.2k 0.7×	1.9k 0.6×	1.3k 0.8×	885 0.7×	1.7k 1.4×	389	5.8k
Zhong Jiang United States	42	1.8k 0.6×	2.2k 0.7×	1.1k 0.6×	1.2k 1.0×	794 0.6×	129	4.6k

Countries citing papers authored by Yves Allory

Since Specialization

Citations

This map shows the geographic impact of Yves Allory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Allory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Allory more than expected).

Fields of papers citing papers by Yves Allory

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Allory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Allory. The network helps show where Yves Allory may publish in the future.

Co-authorship network of co-authors of Yves Allory

This figure shows the co-authorship network connecting the top 25 collaborators of Yves Allory. A scholar is included among the top collaborators of Yves Allory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Allory. Yves Allory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roumiguié, M., Priscilla Léon, Évanguelos Xylinas, et al.. (2024). Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2024–2026 : tumeurs de la vessie n’infiltrant pas le muscle (TVNIM). 34(7). F272–F295. 1 indexed citations

Fontugne, Jacqueline, Jennifer Wong, Luc Cabel, et al.. (2023). Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis. The Journal of Pathology. 259(4). 455–467. 13 indexed citations

Thibault, Constance, Aude Fléchon, Laurence Albigès, et al.. (2023). Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24). European Journal of Cancer. 186. 83–90. 12 indexed citations

Neuzillet, Y., Priscilla Léon, Thomas Seisen, et al.. (2022). A prospective descriptive 1‐year study in France of all BCG therapy dispensations for non‐muscle‐invasive bladder cancer. British Journal of Urology. 131(5). 611–616. 1 indexed citations

Moktefi, Anissa, Ariane Jolly, Pierre de la Grange, et al.. (2022). The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer. British Journal of Cancer. 128(5). 918–927. 10 indexed citations

Groeneveld, Clarice S., Jacqueline Fontugne, Luc Cabel, et al.. (2021). Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. European Journal of Cancer. 148. 181–189. 104 indexed citations

Sirab, Nanor, Damien Drubay, Pascale Maillé, et al.. (2021). Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. The Journal of Pathology. 256(1). 108–118. 12 indexed citations

Kossaï, Myriam, C. Radulescu, Julien Adam, et al.. (2021). Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC. Urologic Oncology Seminars and Original Investigations. 40(1). 12.e1–12.e11. 9 indexed citations

Marqués, Miriam, Robin Tranchant, Luis C. Fernández, et al.. (2020). Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Research. 80(4). 843–856. 21 indexed citations

10.

Garinet, Simon, G. Pignot, Sophie Vacher, et al.. (2018). High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer. Molecular Cancer Research. 17(2). 469–475. 18 indexed citations

11.

Masson-Lecomte, A., Evangelina López de Maturana, Michael E. Goddard, et al.. (2016). Inflammatory-Related Genetic Variants in Non–Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. Cancer Epidemiology Biomarkers & Prevention. 25(7). 1144–1150. 4 indexed citations

12.

Biton, Anne, Isabelle Bernard‐Pierrot, Yinjun Lou, et al.. (2014). Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. Cell Reports. 9(4). 1235–1245. 117 indexed citations

13.

Albigès, Laurence, Justine Guégan, Audrey Le Formal, et al.. (2014). MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array. Clinical Cancer Research. 20(13). 3411–3421. 134 indexed citations

14.

Rouanne, Mathieu, J. Rode, Yves Allory, et al.. (2013). Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: Ten years of follow-up. Scandinavian Journal of Urology. 48(2). 131–137. 15 indexed citations

15.

Rebouissou, Sandra, Aurélie Hérault, Éric Letouzé, et al.. (2012). CDKN2A homozygous deletion is associated with muscle invasion in FGFR3 ‐mutated urothelial bladder carcinoma. The Journal of Pathology. 227(3). 315–324. 77 indexed citations

16.

Chapeaublanc, Elodie, Lisa A. Kirkwood, Rémy Nicolle, et al.. (2012). Deregulation of Rab and Rab Effector Genes in Bladder Cancer. PLoS ONE. 7(6). e39469–e39469. 94 indexed citations

17.

Fritz, Vanessa, Zohra Benfodda, Geneviève Rodier, et al.. (2010). Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice. Molecular Cancer Therapeutics. 9(6). 1740–1754. 231 indexed citations

18.

Ploussard, Guillaume, Stéphane Terry, Pascale Maillé, et al.. (2010). Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Cancer Research. 70(22). 9253–9264. 121 indexed citations

19.

Ploussard, Guillaume, Évanguelos Xylinas, Xavier Durand, et al.. (2010). Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. British Journal of Urology. 108(4). 513–517. 31 indexed citations

20.

Dyrskjøt, Lars, Karsten Zieger, Francisco X. Real, et al.. (2007). Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study. Clinical Cancer Research. 13(12). 3545–3551. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact